Thrombocytopenia PLT < /L ITP DIC HIT SLE HIV-1 < /L CTCAE CTCAE-4.

Transcript

1 Chinese Clinical Oncology Mar Vol. 23 No * -11 rhil-11 rhil-11 rhil-11 rhil R A Thrombocytopenia PLT < /L ITP DIC < /L TTP HIT < /L SLE HIV-1 < /L 1 / AA AL 2-3 CTCAE CTCAE Ⅰ Ⅱ Ⅲ Ⅳ < + 1mmJK + 1mm < WK8ZQ LLN < ~ ~ WK12 /mm /mm WKW PLT < LLN < 025. ~ /L 9 /L LLN lower limit of normal ITP 5 AA ASH 7 *

2 Chinese Clinical Oncology Mar Vol. 23 No rhil IL-11 rhil-11 IL-11 - IL- 11Rα 130 rhil-11 gp130 T AABB 8 rhil-11 CIT 16 PLT < /L 2016 rhil- 11 ITP rhil-11 AA 6 rhil-11 IL-11Rα rhil rhil rhil ITP Th IL-11 rhil IL rhil FDA rhil-11 rhil-11 2 rhil CIT 16 CIT CFDA rhil-11 Ⅲ Ⅳ 14 1 ONS CIT 2014 / rhil-11 CIT 15 CSCO PLT /L PLT 20

3 Chinese Clinical Oncology Mar Vol. 23 No /L 26 rhil-11 rhil-11 rhtpo rhtpo TPO 30 1 Romiplostim Ehmmbopag CIT 16 6 rhil-11 rhtpo CFDA ~ 24 h rhil-11 CIT 50 μg /kg 1 7 ~ /L rhil-11 rhtpo /L rhil-11 2 rhil rhtpo 1 1 CIT CIT secondary prevention 1 16 Ⅲ /Ⅳ ICH AL 31 CIT 1 2 PLT < /L 3 AL 4 5 ECOG 2 6 Ⅲ /Ⅳ IL-11 AML 6 ~ 24 h 32 PLT < /L PLT /L rhil μg /kg primary prevention rhil-11 AL

4 Chinese Clinical Oncology Mar Vol. 23 No rhil-11 6 ~ 24 h rhil μg /kg 1 7 ~ 14 1 rhil ECOG 2 5 AL 2. 3 IL-11 IL-3 SCF PLT /L 19 AL h rhil rhil rhil-11 rhil rhil rhil rhil-11 rhil-11 rhil-11 AML Ⅱ /Ⅲ rhil rhil-11 AA 2. 8% vs % P = 6 rhil μg /kg PLT /L OS DFS 2. 4 ITP rhil-11 ITP IL-11 adipogenesis inhibitory factor AGIF rhil-11 rhil-11 AA 5 rhil rhil-11 ITP PLT < /L ITP

5 Chinese Clinical Oncology Mar Vol. 23 No rhil-11 ITP 17 1 ~ rhil-11 rhil-11 ITP γ rhil μg /kg PLT /L 24 rhil-11 ITP CD4 + T Th1 rhil-11 Th2 T-bet mrna GATA-3 mrna 3 2 kg IL-11 ITP 25 ITP Th1 Th2 Th Th1 T-bet rhil-11 GATA-3 rhil-11 Th1 Clcr < 30 ml /min T-bet GATA-3 25 μg /kg rhil rhil rhil-11 rhil rhil ESC rhil % 1 ~ 2 3 ~ 4 14 rhil rhil-11 5% rhil rhil-11 8% rhil rhil-11 rhil RAAS 43 rhil rhil μg /kg 7. 7% 33 7 ~ 14 h 39

6 Chinese Clinical Oncology Mar Vol. 23 No CHF rhil rhil-11 1 ~ Isaacs C Robert NJ Bailey FA et al. Randomized placebocontrolled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubi- rhil-11 rhil-11 rhil-11 cin J rhil-11 poietic rhil Suppl J J Michelson AD. The clinical approach to disorders of platelet number and function M / /Michelson AD. Platelets 3rd ed. Pittsburgh Academic Press J. 20 Ellis M Zwaan F Hedstr m U et al. Recombinant human interleukin National Cancer Institute. Common terminology criteria for adverse 11 and bacterial infection in patients with haemological malignant disease undergoing chemotherapy a double-blind pla- events CTCAE Version EB /OL cebo-controlled randomised trial J. Lancet https / /ctep. cancer. gov /protocoldevelopment / adverse_effects. htm J J Slichter SJ. Evidence-based platelet transfusion guidelines J. Hematology Am Soc Hematol Educ Program Kaufman RM Djulbegovic B Gernsheimer T et al. Platelet transfusion A clinical practice guideline from the AABB J. Ann Intern Med Tepler I Elias L Hussein M et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy J. Blood J Clin Oncol Schwertschlag US Trepicchio WL Dykstra KH et al. Hemato- immunomodulatory and epithelial effects of interleukin-11 J. Leukemia Turner KJ Neben S Weich N et al. The role of recombinant interleukin 11 in megakaryocytopoiesis J. Stem Cells Pfizer Inc. NEUMEGA Instrument EB /OL https / /www. pfizer. com /products /product-detail / neumega EB / OL http / /www. qilu-pharma. com /products detail /product Id 51. html. 15 Polovich M Whitford JM Olsen M et al. Chemotherapy and biotherapy guidelines and recommendations for practice M. 4th ed. Oncology Nursing Society J M. 19 Keller DC Du XX Srour EF et al. Interleukin-11 inhibits adipogenesis and stimulates myelopoiesis in human long-term marrow cultures J. Blood Usuki K Urabe A Ikeda Y et al. A multicenter randomized

7 Chinese Clinical Oncology Mar Vol. 23 No. 3 double-blind placebo-controlled late-phase Ⅱ /Ⅲ study of recombinant human interleukin 11 in acute myelogenous leukemia J. Int J Hematol J J J. 26 J IL-11 ITP Th1 Th2 T-bet GATA-3 mrna J Lin Y Zhou X Guo W et al. RhIL-11 treatment normalized Th1 /Th2 and T-bet /GATA-3 imbalance in in human immune thrombocytopenic purpura ITP J. Int Immunopharmacol Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy J. Oncology rhtpo rhil-11. biology and clinical use J. Blood AML J. nemia in healthy subjects J. J Clin Pharmacol J J Zamorano JL Lancellotti P Rodriguez MD et al ESC Position Paper on cancer treatments and cardiovascular toxicity de veloped under the auspices of the ESC Committee for Practice J. Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology ESC J Eur J Heart Fail J J Tafuri A Lemoli RM Petrucci MT et al. Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells J. Exp Hematol myocytes as the target of interleukin 11 a cardioprotective cytokine J. Cytokine J signal transducer and activator of transcription 3 by interleukin J. ameliorates cardiac fibrosis after myocardial infarction J. Circulation J J Du X Williams DA. Interleukin-11 review of molecular cell J J Dykstra KH Rogge H Stone A et al. Mechanism and amelioration of recombinant human interleukin-11 rhil-11 -induced a Sartiani L De PP Lonardo G et al. Does recombinant human -11 interleukin-11 exert direct electrophysiologic effects on single human atrial myocytes J. J Cardiovasc Pharmacol Nd SJ. Tolerability and side-effect profile of rhil-11 J. Oncology Kimura R Maeda M Arita A et al. Identification of cardiac 49 Obana M Maeda M Takeda K et al. Therapeutic activation of Nakagawa M Owada Y Izumi Y et al. Four cases of investigational therapy with interleukin-11 against acute myocardial J infarction J. Heart & Vessels